Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)

Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760 million outlook three months earlier. Levi & Korsinsky is investigating potential securities law violations.

Emergent BioSolutions (NYSE: EBS) shareholders absorbed a sharp decline after the Company reduced its FY2026 revenue guidance to $645-$675 million, down from the $720-$760 million range management had reaffirmed on its April 30, 2026 earnings call.

If you lost money on EBS shares, you are encouraged to submit your loss information now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

On February 26, 2026, Emergent issued initial FY2026 guidance of $720-$760 million in revenue and $135-$155 million in adjusted EBITDA. On that same call, Chief Financial Officer Richard S. Lindahl attributed softer NARCAN demand to the prolonged government shutdown and near-term market uncertainty, characterizing those factors as "we view as transient and not reflective of the long-term growth potential in this category." Management further stated that it expected NARCAN to maintain its leading market share, while the accompanying presentation stated that the Company had "[m]aintained market leadership; pricing stabilized."

On April 30, 2026, Emergent reaffirmed its FY2026 revenue guidance of $720–$760 million, leaving the forecast unchanged from February. The Company simultaneously raised its adjusted EBITDA guidance to $155–$175 million from $135–$155 million.

Roughly three months later, on August 5, 2026, Emergent reduced its FY2026 revenue guidance to $645–$675 million from $720–$760 million, a $75 million reduction at the midpoint. The Company also reduced adjusted EBITDA guidance to $130–$150 million from $155–$175 million.

Levi & Korsinsky is investigating whether Emergent's prior guidance statements were adequately supported. Shareholders who purchased EBS stock and sustained losses may have their claims evaluated at no cost , or call (212) 363-7500.

The investigation concerns whether Emergent BioSolutions made materially false or misleading statements regarding its FY2026 revenue and adjusted EBITDA outlook and the Company's characterization of NARCAN demand and pricing. After reaffirming its $720–$760 million FY2026 revenue outlook on April 30, 2026, Emergent cut that range to $645–$675 million on August 5—a $75 million reduction at the midpoint—and reduced adjusted EBITDA guidance to $130–$150 million from $155–$175 million. The Company's guidance reduction was followed by a decline in its stock price, causing losses to investors.

Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.